Net debt/EBITDA společnosti Midatech Pharma Plc
Jaká je hodnota metriky Net debt/EBITDA společnosti Midatech Pharma Plc?
Hodnota metriky Net debt/EBITDA společnosti Midatech Pharma Plc je 1.88
Jaká je definice metriky Net debt/EBITDA?
The net debt to earnings before interest, taxes, depreciation, and amortization (Net debt/EBITDA) ratio measures financial leverage and the company’s ability to pay off its debt. It shows how long it would take the company to pay off all its debt with operations at the current level.
The net debt to EBITDA ratio is calculated as Net debt divided by EBITDA. It is similar to the debt to EBITDA ratio, but cash and cash equivalents are subtracted in net debt.
Net debt = short-term debt + long-term debt - cash and cash equivalents
EBITDA = net income + interest expense + taxes + depreciation + amortization
Lower debt debt to EBITDA ratio indicates the company is not heavily indebted and should be able to repay its obligations. Alternatively, higher ratio indicated the company is excessively indebted. The ratio varies between industries as different industries have different capital requirements. Usually, the ratio should be compared to a benchmark or an industry average to determine the company’s credit risk. Generally, a net debt to EBITDA ratio above 4 or 5 is considered high.
Net debt/EBITDA společností v sektoru Health Care sektor na LSE ve srovnání se společností Midatech Pharma Plc
Čemu se věnuje společnost Midatech Pharma Plc?
Midatech Pharma plc focuses on the research and development of oncology and rare disease products in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant for topical application in psoriasis; and MTD211 and MTD219 for central nervous system and transplant anti-rejection indications. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.
Firmy s metrikou net debt/ebitda podobnou společnosti Midatech Pharma Plc
- Hodnota metriky Net debt/EBITDA společnosti Amaero Intl Ltd je 1.87
- Hodnota metriky Net debt/EBITDA společnosti Neo Battery Materials je 1.87
- Hodnota metriky Net debt/EBITDA společnosti AgEagle Aerial Systems je 1.87
- Hodnota metriky Net debt/EBITDA společnosti Aridis Pharmaceuticals Inc je 1.87
- Hodnota metriky Net debt/EBITDA společnosti Rio2 je 1.87
- Hodnota metriky Net debt/EBITDA společnosti Artelo Biosciences Inc je 1.87
- Hodnota metriky Net debt/EBITDA společnosti Midatech Pharma Plc je 1.88
- Hodnota metriky Net debt/EBITDA společnosti Huaxi je 1.88
- Hodnota metriky Net debt/EBITDA společnosti Kadmon Inc je 1.88
- Hodnota metriky Net debt/EBITDA společnosti Ascentage Pharma Grp Intl je 1.88
- Hodnota metriky Net debt/EBITDA společnosti Great-West Lifeco je 1.88
- Hodnota metriky Net debt/EBITDA společnosti Nabriva Therapeutics Plc je 1.89
- Hodnota metriky Net debt/EBITDA společnosti Austal je 1.89